Gene Editing Breakthroughs Boost Stocks

The world of gene editing is buzzing with excitement. Two companies, Crispr Therapeutics and Intellia Therapeutics, are making waves with their latest findings. Their stocks are on the rise, thanks to promising results in treating high cholesterol and a rare swelling disorder.

Crispr Therapeutics: A One-Time Treatment for High Cholesterol?

Crispr Therapeutics shared some impressive data at a conference. They found that a single dose of their gene-editing drug can lower levels of a protein called ANGPTL3. This protein is linked to high cholesterol and triglycerides. The results suggest that Crispr might have a one-time treatment for people with genetic forms of these conditions.

Intellia Therapeutics: A Functional Cure for Hereditary Angioedema?

Meanwhile, Intellia Therapeutics is celebrating a big win. They treated patients with a severe swelling disorder called hereditary angioedema (HAE). After two years, 10 out of 11 patients had no swelling attacks. The one patient who still had attacks saw a significant reduction. This is a huge deal, as it could mean a "functional cure" for HAE.

Stock Market Reactions

The stock market is taking notice. Crispr's stock rose over 2%, while Intellia's stock jumped more than 7%. This is a big turnaround for Intellia, which saw a sharp drop last week after a patient died during a trial for a different gene-editing drug.

The Future of Gene Editing

These breakthroughs show the potential of gene editing. However, it's important to remember that the field is still new. There are risks and challenges ahead. But for now, the future looks bright for these companies and their innovative treatments.